More on Merck Q4: Net profit falls to $781M

Merck (MRK +2.1%) net profit $781M vs $908M a year earlier,

Earnings were hurt by patent expirations and currency fluctuations.

Sales breakdown: Pharmaceuticals flat at $9.76B, with Januvia +4%, Zetia +9%, Remicade +9%, Janumet +11%, Gardasil -9%; Animal Health -1%, consumer care +1%.

Guidance: 2014 adjusted EPS of $3.35-3.53 vs consensus of $3.48; revenues $42.4-43.2B vs $43.35B. (PR)


From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs